Malaysian Journal of Biochemistry and Molecular Biology (ISSN 1511-2616) Volume 17 No 1 - 2009

Articles

Substitution of GPR Grade Salts in the Production of α-Amylase by Bacillus licheniformis 6346 in Solid State Fermentation Author(s): Vasanthy Arasaratnam, Kulasingam Thayaananthan Category(s): Research paper http://ejum.fsktm.um.edu.my/article/733.pdf

Analysis of Parameters for Fatty Acid Methyl Esters Production from Refined Palm Oil for Use as Biodiesel in the Single- and Two-stage Processes Author(s): Zul Ilham Zulkiflee Lubes, Muhamad Zakaria Category(s): Research paper http://ejum.fsktm.um.edu.my/article/734.pdf

Sequencing and Analysis of a 40 kb Region from the Toxoplasma gondii Genome Author(s): Siew-Fun Wai, King-Hwa Ling, Wai-Yan Yee, Rahmah Mohamed, Kiew-Lian Wan Category(s): Research paper http://ejum.fsktm.um.edu.my/article/735.pdf

Expression of Akt and MAPK in the Normal and Regenerating Peripheral Nerves and Their Dorsal Root Ganglia Author(s): Murali Naidu, Rosie Pamela David, Richard Asher, James Fawcett Category(s): Short communication http://ejum.fsktm.um.edu.my/article/736.pdf

The Angiotensin-Converting Enzyme Inhibitor, Captopril, Alters Some Biochemical Laboratory Measurements In Vitro Author(s): Ibrahim IA, Al-Joudi FS Category(s): Short communication http://ejum.fsktm.um.edu.my/article/737.pdf

Abstracts of the 33rd Annual Conference of the Malaysian Society for Biochemistry and Molecular Biology Author(s): Abstract Category(s): MSBMB conference abstract http://ejum.fsktm.um.edu.my/article/738.pdf

Communicable disease threats report, 10-16 June 2012, week 24

The ECDC communicable disease threats report is a weekly bulletin intended for epidemiologists and health professionals in the area of communicable disease prevention and control. Summarising information gathered by ECDC through its epidemic intelligence activities regarding communicable disease threats of concern to the European Union, it also provides updates on the global situation and changes in the epidemiology of communicable diseases with potential to affect Europe, including diseases that are the focus of eradication efforts.
 http://www.ecdc.europa.eu/en/publications/Publications/CDTR%20online%20version%2015%20June%202012.pdf

Annual epidemiological report 2011 - Reporting on 2009 surveillance data and 2010 epidemic intelligence data

This edition of the Annual Epidemiological Report presents the surveillance data reported to ECDC for 2009 and an analysis of the public health threats detected in 2010 through ECDC’s routine epidemic intelligence.
It provides an overview of communicable diseases in the European Union and describes areas where a more concerted public health response is required in order to decrease the burden of disease on society and healthcare systems.

http://www.ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf

Tuberculosis surveillance and monitoring in Europe 2012

This is the fourth surveillance report launched jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe (WHO/Europe) following on from reports under the EuroTB project, established in 1996.
http://www.ecdc.europa.eu/en/publications/Publications/1203-Annual-TB-Report.pdf

Monitoring the Emergence of Antiretroviral Resistance

The World Health Organization (WHO) has played a leading role in developing
strategies for the surveillance and containment of antimicrobial resistance in bacterial
and parasitic diseases. The goal has been to optimize patient care and to minimize the
emergence and spread of antimicrobial drug resistance. Just as for bacterial and parasitic diseases, a global resistance monitoring programme is also needed for HIV/AIDS. In the developed world the remarkable reduction of HIVrelated morbidity and mortality produced by potent antiretroviral therapy has been
accompanied by an increase in the prevalence of drug-resistant viruses unresponsive to
available therapies. In the developing world, as access to antiretroviral agents increases,
drug resistance may be enhanced by inappropriate treatment and lack of adherence to
treatment regimens. The need to develop a global antiretroviral resistance monitoring programme was
addressed at the consultation organized by WHO in collaboration with the International
AIDS Society (IAS) and the Istituto Superiore di Sanità (ISS) and held in Rome,
October 2000. It was proposed that WHO, in collaboration with IAS, develop a detailed plan of action
involving partnerships with existing antiretroviral (ARV) resistance monitoring centres
and networks. The plan will be based on the following priorities agreed upon by the
participants at the consultation: 

• to identify sites that are currently involved in HIV-1 drug resistance monitoring
activities and to catalogue these activities
• to develop uniform criteria for the collection and reporting of HIV-1 drug resistance
• to develop and maintain a surveillance system that determines HIV-1 drug resistance
among:
• previously untreated patients
• targeted ARV-experienced populations (e.g. those who have a history of ARV
therapy; those who are receiving active therapy; or those who have received
therapy through perinatal transmission prevention programmes)
• to monitor simultaneously the subtype of circulating HIV-1 strains by using protease
and/or reverse transcripts sequences
• to determine trends in the prevalence of drug resistance in different geographical
areas in relation to the introduction of ARV therapy
• to establish linkages between surveillance sites and quality controlled laboratories
and to promote technology transfer of drug resistance testing methodologies to sites
in the developing world
• to promote education about strategies that reduce the selection of antiretroviral
resistance.
http://apps.who.int/medicinedocs/index/assoc/s16347e/s16347e.pdf

Implementing Antimicrobial Drug Resistance Surveillance and Containment for HIV, Tuberculosis and Malaria (923K) (2003)

http://whqlibdoc.who.int/hq/2003/WHO_CDS_CSR_RMD_2003.2.pdf

Antimicrobial Resistance Surveillance Questionnaire for Assessment of National Networks DEPARTMENT OF

Comprehensive quality systems are essential in order to ensure the validity of results from
microbiological investigations and epidemiological analyses in antimicrobial resistance
(AMR) surveillance. To be effective such systems should:
be focused on the organisms of greatest public health importance (i.e. with high mortality
and/or morbidity, and where therapeutic options may be severely limited by antimicrobial
resistance);
include organisms that are readily transmissible (i.e. may give rise to outbreaks and epidemics);
provide information for action at the local, intermediate and national levels.
The laboratories involved must be suitably staffed and equipped in order to produce
meaningful antimicrobial resistance data. The work must be organized in a way that will
detect unacceptable levels of random and systematic errors and initiate remedial actions. The
primary clinical objective of antimicrobial susceptibility testing is to guide the clinician in
the treatment of individual patients. This requires the transmission of valid information to the
decision-maker in a timely manner with appropriate interpretation for the non-expert. For
antimicrobial resistance surveillance networks it is equally important to realize that data
generated for clinical purposes will need to be adapted for epidemiological use. This includes
a precise definition of the population from which the samples are collected. It is also
desirable to include mechanisms to avoid duplicates and to be able to sort isolates according
to specific properties such as specimen type, gender, age, hospital versus community
acquisition of infection, etc. No surveillance programme can fulfil all the suggested criteria,
but a description of the programme needs to address these issues.
The present questionnaire is only one component of a strategy for quality assessment. The
aim is to provide a means for laboratory networks currently active in antimicrobial resistance
surveillance to assess the status of the individual laboratories in the network (Component I)
with respect to basic laboratory capacity and infrastructure (Part 1), the ability to isolate and
identify bacterial isolates (Part 2), and the performance of antimicrobial susceptibility testing
(Part 3). Component II is a tool for evaluation of the network coordinating centre and the
overall functioning of the surveillance network. A comprehensive description of quality
systems specifically tailored for AMR surveillance is presently being prepared by WHO.
http://www.who.int/drugresistance/whocdscsrrmd20031.pdf